Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Ahmed Saleh Ibrahim, Azza Hasan Abd El-Fatah, Ayman Fathy Abd El-Halim & Farid Fawzy Mohamed. (2023) Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major. Journal of Blood Medicine 14, pages 67-81.
Read now
Read now
George J Kontoghiorghes & Christina N Kontoghiorghe. (2019) Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology. Expert Opinion on Investigational Drugs 28:7, pages 593-603.
Read now
Read now
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 465-481.
Read now
Read now
Christina N Kontoghiorghe, Annita Kolnagou & George J Kontoghiorghes. (2013) Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals. Expert Opinion on Investigational Drugs 22:5, pages 591-618.
Read now
Read now
Annita Kolnagou, Konstantinos Natsiopoulos, Marios Kleanthous, Alexia Ioannou & George J. Kontoghiorghes. (2013) Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*. Toxicology Mechanisms and Methods 23:1, pages 48-56.
Read now
Read now
George J Kontoghiorghes. (2013) The Proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. Toxicology Mechanisms and Methods 23:1, pages 1-4.
Read now
Read now
George J. Kontoghiorghes. (2011) A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients. Hemoglobin 35:3, pages 301-311.
Read now
Read now
Annita Kolnagou, Marios Kleanthous & George J. Kontoghiorghes. (2011) Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy. Hemoglobin 35:3, pages 186-198.
Read now
Read now
George J Kontoghiorghes. (2011) The Proceedings Of The 19Th International Conference On Chelation Held In London, United Kingdom: Major Changes In Iron Chelation Therapy In The Last 25 Years Using Deferiprone (L1) Has Resulted In The Complete Treatment Of Iron Overload. Hemoglobin 35:3, pages 181-185.
Read now
Read now
H.P. Nick. (2011) Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251–264]. Hemoglobin 35:2, pages 175-179.
Read now
Read now
George J Kontoghiorghes. (2010) Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opinion on Drug Safety 9:4, pages 633-641.
Read now
Read now
George J. Kontoghiorghes, Aspasia Spyrou & Annita Kolnagou. (2010) Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption. Hemoglobin 34:3, pages 251-264.
Read now
Read now
Annita Kolnagou & George J. Kontoghiorghes. (2010) Maintenance of Normal Range Body Iron Store Levels for up to 4.5 Years in Thalassemia Major Patients Using Deferiprone Monotherapy. Hemoglobin 34:3, pages 204-209.
Read now
Read now
George J. Kontoghiorghes. (2010) The 18th ICOC Proceedings in Athens, Greece: New Breakthrough in Thalassemia Leading to the Complete Treatment of Iron Overload and to Hundreds of Patients Achieving and Maintaining Normal Body Iron Stores. Ethical Questions on Chelation Therapy. Hemoglobin 34:3, pages 199-203.
Read now
Read now
Articles from other publishers (18)
George J. Kontoghiorghes. (2023) Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences 24:23, pages 16749.
Crossref
Crossref
George J. Kontoghiorghes. (2023) The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. Pharmaceuticals 16:7, pages 1016.
Crossref
Crossref
Valeria Marini, Valeria Maria Pinto, Manuela Stella, Carmen Fucile, Francesca Lantieri, Giacomo Luci, Barbara Gianesin, Lorenzo Bacigalupo, Gian Luca Forni & Francesca Mattioli. (2022) Effect of Aging on Deferasirox Therapy in Transfusion-dependent Patients. A Prospective-
Retrospective, Cohort-study. Current Drug Metabolism 23:13, pages 1072-1079.
Crossref
Crossref
Hatice Deniz Sangu, Semra Akgönüllü & Adil Denizli. (2021) Ion-imprinted-based nanochelators for iron(III) removal from synthetic gastric fluid. Polymer Bulletin 79:10, pages 8947-8965.
Crossref
Crossref
George J. Kontoghiorghes. (2022) Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. International Journal of Molecular Sciences 23:12, pages 6735.
Crossref
Crossref
George J. Kontoghiorghes. (2021) Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines 8:7, pages 36.
Crossref
Crossref
George Kontoghiorghes & Christina Kontoghiorghe. (2020) Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 9:6, pages 1456.
Crossref
Crossref
Pairash Saiviroonporn, Pornpim Korpraphong, Vip Viprakasit & Rungroj Krittayaphong. (2018) An Automated Segmentation of R2* Iron-Overloaded Liver Images Using a Fuzzy C-Mean Clustering Scheme. Journal of Computer Assisted Tomography 42:3, pages 387-398.
Crossref
Crossref
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) New developments and controversies in iron metabolism and iron chelation therapy. World Journal of Methodology 6:1, pages 1.
Crossref
Crossref
Pairash Saiviroonporn, Vip Viprakasit & Rungroj Krittayaphong. (2015) Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme. BMC Medical Imaging 15:1.
Crossref
Crossref
Christina Kontoghiorghe, Annita Kolnagou & George Kontoghiorghes. (2015) Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology. Molecules 20:11, pages 20841-20872.
Crossref
Crossref
Annita Kolnagou. (2014) Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World Journal of Methodology 4:4, pages 197.
Crossref
Crossref
Christina N Kontoghiorghe. (2014) World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World Journal of Methodology 4:3, pages 163.
Crossref
Crossref
S.J.S. Flora. 2013. Comprehensive Inorganic Chemistry II. Comprehensive Inorganic Chemistry II
987
1013
.
Pairash Saiviroonporn, Vip Viprakasit, Kleebsabai Sanpakit, John C. Wood & Rungroj Krittayaphong. (2012) Intersite validations of the pixel-wise method for liver R2* analysis in transfusion-dependent thalassemia patients: a more accessible and affordable diagnostic technology. Hematology/Oncology and Stem Cell Therapy 5:2, pages 91-95.
Crossref
Crossref
Adrianna Vlachos & Ellen Muir. (2010) How I treat Diamond-Blackfan anemia. Blood 116:19, pages 3715-3723.
Crossref
Crossref
Jill Waalen. (2010) More pieces to the iron chelation puzzle. Translational Research 156:2, pages 53-54.
Crossref
Crossref
Annita Kolnagou & George J. Kontoghiorghes. (2010) New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. British Journal of Haematology, pages no-no.
Crossref
Crossref